BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34590000)

  • 1. Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria-Reducing Race Disparities.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    JTO Clin Res Rep; 2021 Mar; 2(3):100137. PubMed ID: 34590000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    J Thorac Oncol; 2020 Nov; 15(11):1738-1747. PubMed ID: 32822843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Guzman A; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    Chest; 2022 Jan; 161(1):248-256. PubMed ID: 34252436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Tammemägi MC; Ruparel M; Tremblay A; Myers R; Mayo J; Yee J; Atkar-Khattra S; Yuan R; Cressman S; English J; Bedard E; MacEachern P; Burrowes P; Quaife SL; Marshall H; Yang I; Bowman R; Passmore L; McWilliams A; Brims F; Lim KP; Mo L; Melsom S; Saffar B; Teh M; Sheehan R; Kuok Y; Manser R; Irving L; Steinfort D; McCusker M; Pascoe D; Fogarty P; Stone E; Lam DCL; Ng MY; Vardhanabhuti V; Berg CD; Hung RJ; Janes SM; Fong K; Lam S
    Lancet Oncol; 2022 Jan; 23(1):138-148. PubMed ID: 34902336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
    Choi E; Ding VY; Luo SJ; Ten Haaf K; Wu JT; Aredo JV; Wilkens LR; Freedman ND; Backhus LM; Leung AN; Meza R; Lui NS; Haiman CA; Park SL; Le Marchand L; Neal JW; Cheng I; Wakelee HA; Tammemägi MC; Han SS
    JAMA Oncol; 2023 Dec; 9(12):1640-1648. PubMed ID: 37883107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review.
    Williams RM; Kareff SA; Sackstein P; Roy T; Luta G; Kim C; Taylor KL; Tammemägi MC
    Lung Cancer; 2022 Jul; 169():55-60. PubMed ID: 35644087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
    Pu CY; Lusk CM; Neslund-Dudas C; Gadgeel S; Soubani AO; Schwartz AG
    JAMA Oncol; 2022 Mar; 8(3):374-382. PubMed ID: 35024781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study.
    Aredo JV; Choi E; Ding VY; Tammemägi MC; Ten Haaf K; Luo SJ; Freedman ND; Wilkens LR; Le Marchand L; Wakelee HA; Meza R; Park SL; Cheng I; Han SS
    JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35642317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data.
    Williams RM; Li T; Luta G; Wang MQ; Adams-Campbell L; Meza R; Tammemägi MC; Taylor KL
    Cancer; 2022 May; 128(9):1812-1819. PubMed ID: 35201610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening.
    Smeltzer MP; Liao W; Faris NR; Fehnel C; Goss J; Shepherd CJ; Ramos R; Qureshi T; Mukhopadhyay A; Ray MA; Osarogiagbon RU
    J Thorac Oncol; 2023 Feb; 18(2):158-168. PubMed ID: 36208717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers.
    Aldrich MC; Mercaldo SF; Sandler KL; Blot WJ; Grogan EL; Blume JD
    JAMA Oncol; 2019 Sep; 5(9):1318-1324. PubMed ID: 31246249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies.
    Ten Haaf K; Bastani M; Cao P; Jeon J; Toumazis I; Han SS; Plevritis SK; Blom EF; Kong CY; Tammemägi MC; Feuer EJ; Meza R; de Koning HJ
    J Natl Cancer Inst; 2020 May; 112(5):466-479. PubMed ID: 31566216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of using risk models for eligibility selection to the International lung screening Trial.
    Cressman S; Weber MF; Ngo PJ; Wade S; Behar Harpaz S; Caruana M; Tremblay A; Manser R; Stone E; Atkar-Khattra S; Karikios D; Ho C; Fernandes A; Yi Weng J; McWilliams A; Myers R; Mayo J; Yee J; Yuan R; Marshall HM; Fong KM; Lam S; Canfell K; Tammemägi MC
    Lung Cancer; 2023 Feb; 176():38-45. PubMed ID: 36592498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities of National Lung Cancer Screening Guidelines in the US Population.
    Han SS; Chow E; Ten Haaf K; Toumazis I; Cao P; Bastani M; Tammemagi M; Jeon J; Feuer EJ; Meza R; Plevritis SK
    J Natl Cancer Inst; 2020 Nov; 112(11):1136-1142. PubMed ID: 32040195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Risk Factor-Based Guidelines and Model-Based Chest CT Lung Cancer Screening in World Trade Center-Exposed Fire Department Rescue/Recovery Workers.
    Cleven KL; Vaeth B; Zeig-Owens R; Colbeth HL; Jaber N; Schwartz T; Weiden MD; Markowitz SB; Silvestri GA; Prezant DJ
    Chest; 2021 May; 159(5):2060-2071. PubMed ID: 33279511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
    Potter AL; Xu NN; Senthil P; Srinivasan D; Lee H; Gazelle GS; Chelala L; Zheng W; Fintelmann FJ; Sequist LV; Donington J; Palmer JR; Yang CJ
    J Clin Oncol; 2024 Mar; ():JCO2301780. PubMed ID: 38537159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the accuracy of the PLCO
    Jantzen R; Ezer N; Camilleri-Broët S; Tammemägi MC; Broët P
    CMAJ Open; 2023; 11(2):E314-E322. PubMed ID: 37041013
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.